• Medientyp: E-Artikel
  • Titel: Multimodal Treatment of Nasopharyngeal Carcinoma in Children, Adolescents and Young Adults-Extended Follow-Up of the NPC-2003-GPOH Study Cohort and Patients of the Interim Cohort
  • Beteiligte: Römer, Tristan; Franzen, Sabrina; Kravets, Hanna; Farrag, Ahmed; Makowska, Anna; Christiansen, Hans; Eble, Michael J.; Timmermann, Beate; Staatz, Gundula; Mottaghy, Felix M.; Bührlen, Martina; Hagenah, Ulrich; Puzik, Alexander; Driever, Pablo Hernáiz; Greiner, Jeanette; Jorch, Norbert; Tippelt, Stephan; Schneider, Dominik T.; Kropshofer, Gabriele; Overbeck, Tobias R.; Christiansen, Holger; Brozou, Triantafyllia; Escherich, Gabriele; Becker, Martina; [...]
  • Erschienen: MDPI AG, 2022
  • Erschienen in: Cancers, 14 (2022) 5, Seite 1261
  • Sprache: Englisch
  • DOI: 10.3390/cancers14051261
  • ISSN: 2072-6694
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Nasopharyngeal carcinoma (NPC) in children and young adults has been treated within two consecutive prospective trials in Germany, the NPC-91 and the NPC-2003 study of the German Society of Pediatric Oncology and Hematology (GPOH). In these studies, multimodal treatment with induction chemotherapy, followed by radio (chemo)therapy and interferon-beta maintenance, yielded promising survival rates even after adapting total radiation doses to tumor response. The outcome of 45 patients in the NPC-2003 study was reassessed after a median follow-up of 85 months. In addition, we analyzed 21 further patients after closure of the NPC-2003 study, recruited between 2011 and 2017, and treated as per the NPC-2003 study protocol. The EFS and OS of 66 patients with locoregionally advanced NPC were 93.6% and 96.7%, respectively, after a median follow-up of 73 months. Seven patients with CR after induction therapy received a reduced radiation dose of 54 Gy; none relapsed. In young patients with advanced locoregional NPC, excellent long-term survival rates can be achieved by multimodal treatment, including interferon-beta. Radiation doses may be reduced in patients with complete remission after induction chemotherapy and may limit radiogenic late effects.
  • Zugangsstatus: Freier Zugang